ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BIOE Bio Essence Corporation (PK)

0.24
-0.01885 (-7.28%)
Last Updated: 16:20:21
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bio Essence Corporation (PK) USOTC:BIOE OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01885 -7.28% 0.24 0.24 0.285 0.241275 0.225 0.2251 45,250 16:20:21

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

13/05/2022 9:39pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 12b-25

  

NOTIFICATION OF LATE FILING

 

(Check one):      

☐  Form 10-K   ☐  Form 20-F    ☐  Form 11-K   ☒  Form 10-Q

☐ Form 10-D    ☐  Form N-SAR    ☐  Form N-CSR

   
    For Period Ended: March 31, 2022
   
    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form N-SAR
   
    For the Transition Period Ended:     
 

Read Instruction Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  

 

PART I — REGISTRANT INFORMATION

 

BIO ESSENCE CORP.

(Full Name of Registrant)

 

8 Studebaker Drive, Irvine CA 92618

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

1

 

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 

         

 

 

 

☒   

  (a)  

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

 

  (b)  

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

  (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

 

PART III — NARRATIVE

 

Bio Essence Corp. (the “Company”), is unable to file, without unreasonable effort or expense, its quarterly report on Form 10-Q for the period ending March 31, 2022 (the “Form 10-Q”). Additional time is needed for the Company’s independent registered public accounting firm to complete its review of the unaudited financial statements included in the Form 10-Q and for the Company to provide additional information to its accountants and auditors in order to produce a complete, accurate annual report. The Company intends on filing its Form 10-Q for the period ending March 31, 2022 on or before May 20, 2022.

 

PART IV — OTHER INFORMATION

 (1) Name and telephone number of person to contact in regard to this notification
   
Ms. Yin Yan       (949)       706-9966
(Name)       (Area Code)       (Telephone Number)
   
 (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).    ☒  Yes    ☐ No
 (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?      ☐  Yes  ☒ No
                   

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

 

 

SIGNATURES

 

Bio Essence Corp., has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

   
Date: May 13, 2022 By:  /s/ Yin Yan
    Yin Yan
Chief Executive Officer

 

3

 

1 Year Bio Essence (PK) Chart

1 Year Bio Essence (PK) Chart

1 Month Bio Essence (PK) Chart

1 Month Bio Essence (PK) Chart

Your Recent History

Delayed Upgrade Clock